Format

Send to

Choose Destination
See comment in PubMed Commons below
Hum Vaccin. 2009 Apr;5(4):264-7. Epub 2009 Apr 30.

Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins.

Author information

1
Equipe Interactions des bactéries commensales et probiotiques avec l'hôte, Unité d'Ecologie et physiologie du Système Digestif, INRA 0910, Jouy-en-Josas, France. luis.bermudez@jouy.inra.fr

Abstract

Food-grade lactic acid bacteria (LAB) have been safely consumed by humans for centuries in fermented foods. Lactococcus lactis, a LAB widely used in the dairy industry as a starter, can be genetically engineered to efficiently produce a large variety of proteins. This feature has been recently exploited by scientists for the development of a new generation of vectors to deliver therapeutic proteins to the mucosal tissues. The successful Phase I clinical trial with a L. lactis strain secreting interleukin-10 for Crohn's disease has opened new horizons for the use of genetically engineered LAB as delivery vehicles. This commentary reviews the current advances made with L. lactis as live vector for the mucosal delivery of therapeutic proteins.

PMID:
19202351
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center